% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wagemann:276151,
      author       = {Wagemann, Olivia and Brendel, Matthias and Franzmeier,
                      Nicolai and Nübling, Georg and Gnoerich, Johannes and
                      Zaganjori, Mirlind and Prix, Catharina and Stockbauer, Anna
                      and Wlasich, Elisabeth and Loosli, Sandra V and Sandkühler,
                      Katja and Frontzkowski, Lukas and Höglinger, Günter and
                      Levin, Johannes},
      title        = {{F}easibility and potential diagnostic value of
                      [18{F}]{PI}-2620 {PET} in patients with down syndrome and
                      {A}lzheimer's disease: a case series.},
      journal      = {Frontiers in neuroscience},
      volume       = {18},
      issn         = {1662-4548},
      address      = {Lausanne},
      publisher    = {Frontiers Research Foundation},
      reportid     = {DZNE-2025-00223},
      pages        = {1505999},
      year         = {2025},
      abstract     = {Adults with Down Syndrome (DS) have a substantially
                      increased risk for Alzheimer's disease (AD) due to the
                      triplicated amyloid-precursor-protein gene on chromosome 21,
                      resulting in amyloid and tau accumulation. However, tau PET
                      assessments are not sufficiently implemented in DS-AD
                      research or clinical work-up, and second-generation tau
                      tracers such as [18F]PI-2620 have not been thoroughly
                      characterized in adults with DS. We aim at illustrating
                      feasibility and potential diagnostic value of tau PET
                      imaging with [18F]PI-2620 for the diagnosis of DS-AD.Five
                      adults with DS $(40\%$ female, aged 43-62) and cognitive
                      decline underwent clinical assessments, neuropsychological
                      testing, lumbar puncture and multimodal neuroimaging. All
                      underwent [18F]PI-2620 tau PET. Visual read of tau PET scans
                      was performed by three blinded raters, assessing increased
                      tracer uptake in brain areas corresponding to the six Braak
                      stage regions and basal ganglia.Visual read of tau burden
                      revealed three tau-positive individuals which corresponded
                      to their clinical decline while two cognitively stable
                      individuals were rated as negative. Rating showed high
                      inter-rater reliability for all Braak stages.Tau PET imaging
                      is a feasible and important biomarker assessment in the
                      differential diagnosis of cognitive decline in adults with
                      DS at risk of developing AD.},
      keywords     = {18F-PI-2620 (Other) / Alzheimer (Other) / case series
                      (Other) / down syndrome (Other) / tau PET (Other) / trisomy
                      21 (Other)},
      cin          = {Clinical Research (Munich) / AG Levin / AG Simons},
      ddc          = {610},
      cid          = {I:(DE-2719)1111015 / I:(DE-2719)1111016 /
                      I:(DE-2719)1110008},
      pnm          = {353 - Clinical and Health Care Research (POF4-353) / 351 -
                      Brain Function (POF4-351)},
      pid          = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-351},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39834700},
      pmc          = {pmc:PMC11744071},
      doi          = {10.3389/fnins.2024.1505999},
      url          = {https://pub.dzne.de/record/276151},
}